Art. -Nr.: HY-15440A

Fostemsavir

(Synonyms: BMS-663068)

2 Cited Publications

Kundenbewertung

Based on 2 publication(s) in Google Scholar

Fostemsavir (BMS-663068) is the phosphonooxymethyl prodrug of BMS-626529. Fostemsavir (BMS-663068) is a novel attachment inhibitor that targets HIV-1 gp120 and prevents its binding to CD4⁺ T cells.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.69%
CAS. Nr.: 864953-29-7
Formel: C₂₅H₂₆N₇O₈P
Molecular Weight:583.49

Speicherung:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Fostemsavir Chemical Structure

CAS. Nr.: 864953-29-7

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vivo
- Clinical Trial
Chemical Information
Publications (2)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

HIV-1

Alle HIV Isoform-spezifische Produkte anzeigen :

In Vivo

Fostemsavir (BMS-663068) has good antiviral activity in subjects infected with virus shown to be susceptible (IC₅₀, <100 nM) to the agent^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 864953-29-7
Appearance Solid
Molecular Weight 583.49
Formel C₂₅H₂₆N₇O₈P
Color White to off-white
SMILES

O=C(N1CCN(C(C2=CC=CC=C2)=O)CC1)C(C3=CN(COP(O)(O)=O)C4=C3C(OC)=CN=C4N5N=C(C)N=C5)=O
Synonyms

BMS-663068
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (2)

All

Sort by:

Journal Impact Factor

J Photochem Photobiol A Chem

2025 Nov 15;473:116930.
J Chromatogr B Analyt Technol Biomed Life Sci

Development, validation and clinical implementation of a HPLC-MS/MS method for the simultaneous quantification of bictegravir, emtricitabine, doravirine, cabotegravir, lenacapavir, fostemsavir, tenofovir alafenamide and the corresponding metabolites temsavir and tenofovir, in human plasma. [Abstract]

2025 Dec 15:1267:124803. PMID: 41072339

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 50 mg/mL (85.69 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 20 mg/mL (34.28 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7138 mL

8.5691 mL

17.1383 mL

5 mM

0.3428 mL

1.7138 mL

3.4277 mL

10 mM

0.1714 mL

0.8569 mL

1.7138 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 8.33 mg/mL (14.28 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Nowicka-Sans B, et al. In vitro antiviral characteristics of HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068. Antimicrob Agents Chemother. 2012 Jul;56(7):3498-507. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	1.7138 mL	8.5691 mL	17.1383 mL	42.8456 mL
	5 mM	0.3428 mL	1.7138 mL	3.4277 mL	8.5691 mL
	10 mM	0.1714 mL	0.8569 mL	1.7138 mL	4.2846 mL
	15 mM	0.1143 mL	0.5713 mL	1.1426 mL	2.8564 mL
	20 mM	0.0857 mL	0.4285 mL	0.8569 mL	2.1423 mL
	25 mM	0.0686 mL	0.3428 mL	0.6855 mL	1.7138 mL
	30 mM	0.0571 mL	0.2856 mL	0.5713 mL	1.4282 mL
DMSO	40 mM	0.0428 mL	0.2142 mL	0.4285 mL	1.0711 mL
	50 mM	0.0343 mL	0.1714 mL	0.3428 mL	0.8569 mL
	60 mM	0.0286 mL	0.1428 mL	0.2856 mL	0.7141 mL
	80 mM	0.0214 mL	0.1071 mL	0.2142 mL	0.5356 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Fostemsavir

2 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Fostemsavir

Anti-Infection Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Peptidomimetic Library

Drug Repurposing Compound Library

Covalent Screening Library

Anti-COVID-19 Compound Library

FDA Approved & Pharmacopeial Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

Human Metabolite Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Fostemsavir

Alle HIV Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Fostemsavir

Anti-Infection Compound Library

FDA-Approved Drug Library

Antiviral Compound Library

Peptidomimetic Library

Drug Repurposing Compound Library

Covalent Screening Library

Anti-COVID-19 Compound Library

FDA Approved & Pharmacopeial Drug Library

Pediatric Drug Library

EMA-Approved Drug Library

Human Metabolite Library

Off-patent Drug Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Covalent Screening Library Plus

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

Mass Spectrometry Human Metabolite Library

Publications Citing Use of MedChemExpress (MCE) Fostemsavir

Alle HIV Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (2)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

Fostemsavir Related Classifications

HY-15440A Related Classifications